| TGF-beta 1 elevates P-gp and BCRP in hepatocellular carcinoma through HOTAIR/miR-145 axis |
9 |
| Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator, in rats and monkeys |
8 |
| Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis |
7 |
| The impact of low temperature on fraction unbound for plasma and tissue |
7 |
| Use of fluorescein isothiocyanate isomer I to study the mechanism of intestinal absorption of fucoidan sulfate in vivo and in vitro |
6 |
| Pharmacokinetics and Pharmacodynamics of Curcumin in regulating anti-inflammatory and epigenetic gene expression |
6 |
| Functional characterization for polymorphic organic anion transporting polypeptides (OATP/SLCO1B 1B 2B1) of monkeys recombinantly expressed with various OATP probes |
5 |
| Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albumin in vivo rats and in vitro study using inductively coupled plasma-mass spectrometory |
4 |
| A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys |
4 |
| Screening of ten cytochrome P450 enzyme activities with 12 probe substrates in human liver microsomes using cocktail incubation and liquid chromatography-tandem mass spectrometry |
3 |
| Development of a Korean-specific virtual population for physiologically based pharmacokinetic modelling and simulation |
3 |
| Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates |
3 |
| Cytochrome P450 2C9-natural antiarthritic interactions: Evaluation of inhibition magnitude and prediction from in vitro data |
3 |
| Contribution of equilibrative nucleoside transporter(s) to intestinal basolateral and apical transports of anticancer trifluridine |
3 |
| Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software |
3 |
| Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies |
3 |
| Human UGT2B7 is the major isoform responsible for the glucuronidation of clopidogrel carboxylate |
3 |
| Alterations in gene expression in vitamin D-deficiency: Down-regulation of liver Cyp7a1 and renal Oat3 in mice |
2 |
| Minimal impact of hepatic and renal impairment on plasma protein binding of lenvatinib, and identification of its major plasma binding protein |
2 |
| Renal vectorial transport of berberine mediated by organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins 1 (MATE1) in rats |
2 |
| Evaluation of the metabolic capability of primary human hepatocytes in three-dimensional cultures on microstructural plates |
2 |
| Amorphous solid dispersions of carvedilol along with pH-modifiers improved pharmacokinetic properties under hypochlorhydoria |
2 |
| Integrating theoretical and experimental permeability estimations for provisional biopharmaceutical classification: Application to the WHO essential medicines |
2 |
| Application of data mining approach to identify drug subclasses based on solubility and permeability |
2 |
| Identification of specific UGT1A9-mediated glucuronidation of licoricidin in human liver microsomes |
2 |
| Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example |
2 |
| Population pharmacokinetics of gliclazide in normal and diabetic rabbits |
2 |
| An iminium ion metabolite hampers the production of the pharmacologically active metabolite of a multikinase inhibitor KW-2449 in primates: irreversible inhibition of aldehyde oxidase and covalent binding with endogenous proteins |
2 |
| Use of generally recognized as safe or dietary compounds to inhibit buprenorphine metabolism: potential to improve buprenorphine oral bioavailability |
2 |
| Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies |
2 |
| Effect of endogenous multidrug resistance 1 and P-glycoprotein expression on anticancer drug resistance in colon cancer cell lines |
1 |
| Application of a physiologically-based pharmacokinetic model for the prediction of bumetanide plasma and brain concentrations in the neonate |
1 |
| Inhibitory effects of sulfonylureas and non-steroidal anti-inflammatory drugs on in vitro metabolism of canagliflozin in human liver microsomes |
1 |
| Pharmacokinetic modeling of the blood-stable camptothecin analog AR-67 in two different formulations |
1 |
| Investigating the bioavailabilities of olerciamide A via the rat's hepatic, gastric and intestinal first-pass effect models |
1 |
| Effects of generally recognized as safe (GRAS) and dietary compounds on phenylephrine metabolism in LS180 human intestinal cells |
1 |
| Effect of renal ischemia on urinary excretion of lithium in rats |
1 |
| Co-administration of nuciferine reduces the concentration of metformin in liver via differential inhibition of hepatic drug transporter OCT1 and MATE1 |
1 |
| Pharmacokinetic interference of doxorubicin with tolbutamide due to reduced metabolic clearance with increased serum unbound fraction in rats |
1 |
| Black tea extract and theaflavin derivatives affect the pharmacokinetics of rosuvastatin by modulating organic anion transporting polypeptide (OATP) 2B1 activity |
1 |
| Pharmacokinetics and tissue distribution of 4-diaminopyridine in rats |
1 |
| Biopharmaceutics classification and intestinal absorption of chikusetsusaponin IVa |
1 |
| Pharmacokinetic and pharmacodynamic model for analysis of adalimumab administered for Crohn's disease |
1 |
| Profiling of hepatic metabolizing enzymes and nuclear receptors in rats with adjuvant arthritis by targeted proteomics |
1 |
| Effects of renal impairment on transporter-mediated renal reabsorption of drugs and renal drug-drug interactions: A simulation-based study |
1 |
| Species differences in metabolism of a new antiepileptic drug candidate, DSP-0565 [2-(2 '-fluoro[1 '-biphenyl]-2-yl)acetamide] |
1 |
| Strain-specific altered nicotine metabolism in 3 '-diindolylmethane (DIM) exposed mice |
1 |
| Theoretical consideration of the properties of intestinal flow models on route-dependent drug removal: Segregated Flow (SFM) vs. Traditional (TM) |
1 |
| Metabolism of steroids by cytochrome P450 2C9 variants |
1 |
| CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib |
1 |
